Viola, D., Dona, A., Caserta, E., Troadec, E., Besi, F., McDonald, T., Ghoda, L., Gunes, E. G., Sanchez, J. F., Khalife, J., Martella, M., Karanes, C., Htut, M., Wang, X., Rosenzweig, M., Chowdhury, A., Sborov, D., Miles, R. R., Yazaki, P. J., Ebner, T., … Pichiorri, F. (2021). Daratumumab induces mechanisms of immune activation through CD38+ NK cell targeting. Leukemia, 35(1), 189–200.
Lewinsky, H., Gunes, E. G., David, K., Radomir, L., Kramer, M. P., Pellegrino, B., Perpinial, M., Chen, J., He, T. F., Mansour, A. G., Teng, K. Y., Bhattacharya, S., Caserta, E., Troadec, E., Lee, P., Feng, M., Keats, J., Krishnan, A., Rosenzweig, M., Yu, J., … Shachar, I. (2021). CD84 is a regulator of the immunosuppressive microenvironment in multiple myeloma. JCI insight, 6(4), e141683.
Ghose, J., Dona, A., Murtadha, M., Gunes, E. G., Caserta, E., Yoo, J. Y., Russell, L., Jaime-Ramirez, A. C., Barwick, B. G., Gupta, V. A., Sanchez, J. F., Sborov, D. W., Rosen, S. T., Krishnan, A., Boise, L. H., Kaur, B., Hofmeister, C. C., & Pichiorri, F. (2021). Oncolytic herpes simplex virus infects myeloma cells in vitro and in vivo. Molecular therapy oncolytics, 20, 519–531.
Adhikarla, V., Awuah, D., Brummer, A. B., Caserta, E., Krishnan, A., Pichiorri, F., Minnix, M., Shively, J. E., Wong, J. Y. C., Wang, X., & Rockne, R. C. (2021). A Mathematical Modeling Approach for Targeted Radionuclide and Chimeric Antigen Receptor T Cell Combination Therapy. Cancers, 13(20), 5171.
Usmani, S. Z., Garfall, A. L., van de Donk, N. W. C. J., Nahi, H., San-Miguel, J. F., Oriol, A., Rosinol, L., Chari, A., Bhutani, M., Karlin, L., Benboubker, L., Pei, L., Verona, R., Girgis, S., Stephenson, T., Elsayed, Y., Infante, J., Goldberg, J. D., Banerjee, A., Mateos, M. V., … Krishnan, A. (2021). Teclistamab, a B-cell maturation antigen x CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study. Lancet (London, England), 398(10301), 665–674.
Jakubowiak, A., Usmani, S. Z., Krishnan, A., Lonial, S., Comenzo, R. L., Wang, J., de Boer, C., Deraedt, W., Weiss, B. M., Schecter, J. M., & Chari, A. (2021). Daratumumab Plus Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma. Clinical lymphoma, myeloma & leukemia, 21(10), 701–710.
Sahebi, F., Eikema, D. J., Koster, L., Kroger, N., Meijer, E., van Doesum, J. A., Rovira, M., Koc, Y., Angelucci, E., Blaise, D., Sammassimo, S., McDonald, A., Arroyo, C. H., Sanchez, J. F., Forcade, E., Castagna, L., Stölzel, F., Sanz, J., Tischer, J., Ciceri, F., … Schönland, S. (2021). Post-Transplantation Cyclophosphamide for Graft-versus- Host Disease Prophylaxis in Multiple Myeloma Patients Who Underwent Allogeneic Hematopoietic Cell Transplantation: First Comparison by Donor Type. A Study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation. Transplantation and cellular therapy, 27(12), 999.e1–999.e10.
Kastritis, E., Palladini, G., Minnema, M. C., Wechalekar, A. D., Jaccard, A., Lee, H. C., Sanchorawala, V., Gibbs, S., Mollee, P., Venner, C. P., Lu, J., Schönland, S., Gatt, M. E., Suzuki, K., Kim, K., Cibeira, M. T., Beksac, M., Libby, E., Valent, J., Hungria, V., … ANDROMEDA Trial Investigators (2021). Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis. The New England journal of medicine, 385(1), 46–58.
Premkumar, V. J., Lentzsch, S., Pan, S., Bhutani, D., Richter, J., Jagannath, S., Liedtke, M., Jaccard, A., Wechalekar, A. D., Comenzo, R., Sanchorawala, V., Royer, B., Rosenzweig, M., Valent, J., Schönland, S., Fonseca, R., Wong, S., & Kapoor, P. (2021). Venetoclax induces deep hematologic remissions in t(11;14) relapsed/refractory AL amyloidosis. Blood cancer journal, 11(1), 10.
Usmani, S. Z., Hoering, A., Ailawadhi, S., Sexton, R., Lipe, B., Hita, S. F., Valent, J., Rosenzweig, M., Zonder, J. A., Dhodapkar, M., Callander, N., Zimmerman, T., Voorhees, P. M., Durie, B., Rajkumar, S. V., Richardson, P. G., Orlowski, R. Z., & SWOG1211 Trial Investigators (2021). Bortezomib, lenalidomide, and dexamethasone with or without elotuzumab in patients with untreated, high-risk multiple myeloma (SWOG-1211): primary analysis of a randomised, phase 2 trial. The Lancet. Haematology, 8(1), e45–e54.
Berdeja, J. G., Madduri, D., Usmani, S. Z., Jakubowiak, A., Agha, M., Cohen, A. D., Stewart, A. K., Hari, P., Htut, M., Lesokhin, A., Deol, A., Munshi, N. C., O'Donnell, E., Avigan, D., Singh, I., Zudaire, E., Yeh, T. M., Allred, A. J., Olyslager, Y., Banerjee, A., … Jagannath, S. (2021). Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. Lancet (London, England), 398(10297), 314–324.
Moreau, P., Garfall, A. L., van de Donk, N. W. C. J., Nahi, H., San-Miguel, J. F., Oriol, A., Nooka, A. K., Martin, T., Rosinol, L., Chari, A., Karlin, L., Benboubker, L., Mateos, M. V., Bahlis, N., Popat, R., Besemer, B., Martínez-López, J., Sidana, S., Delforge, M., Pei, L., … Usmani, S. Z. (2022). Teclistamab in Relapsed or Refractory Multiple Myeloma. The New England journal of medicine, 387(6), 495–505.
Richardson, P. G., Jacobus, S. J., Weller, E. A., Hassoun, H., Lonial, S., Raje, N. S., Medvedova, E., McCarthy, P. L., Libby, E. N., Voorhees, P. M., Orlowski, R. Z., Anderson, L. D., Jr, Zonder, J. A., Milner, C. P., Gasparetto, C., Agha, M. E., Khan, A. M., Hurd, D. D., Gowin, K., Kamble, R. T., … DETERMINATION Investigators (2022). Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma. The New England journal of medicine, 387(2), 132–147.
Weisel, K., Krishnan, A., Schecter, J. M., Vogel, M., Jackson, C. C., Deraedt, W., Yeh, T. M., Banerjee, A., Yalniz, F., Nesheiwat, T., Van Sanden, S., Diels, J., Valluri, S., Usmani, S. Z., Berdeja, J. G., Jagannath, S., & Martin, T. (2022). Matching-Adjusted Indirect Treatment Comparison to Assess the Comparative Efficacy of Ciltacabtagene Autoleucel in CARTITUDE-1 Versus Belantamab Mafodotin in DREAMM-2, Selinexor-Dexamethasone in STORM Part 2, and Melphalan Flufenamide-Dexamethasone in HORIZON for the Treatment of Patients With Triple-Class Exposed Relapsed or Refractory Multiple Myeloma. Clinical lymphoma, myeloma & leukemia, 22(9), 690–701.
D'Souza, A., Brazauskas, R., Stadtmauer, E. A., Pasquini, M. C., Hari, P., Bashey, A., Callander, N., Devine, S., Efebera, Y., Ganguly, S., Gasparetto, C., Geller, N., Horowitz, M. M., Koreth, J., Landau, H., Brunstein, C., McCarthy, P., Qazilbash, M. H., Giralt, S., Krishnan, A., … Flynn, K. E. (2023). Trajectories of quality of life recovery and symptom burden after autologous hematopoietic cell transplantation in multiple myeloma. American journal of hematology, 98(1), 140–147.
Dispenzieri, A., Krishnan, A., Arendt, B., Blackwell, B., Wallace, P. K., Dasari, S., Vogl, D. T., Efebera, Y., Fei, M., Geller, N., Giralt, S., Hahn, T., Howard, A., Kohlhagen, M., Landau, H., Hari, P., Pasquini, M. C., Qazilbash, M. H., McCarthy, P., Shah, N., … Murray, D. (2022). Mass-Fix better predicts for PFS and OS than standard methods among multiple myeloma patients participating on the STAMINA trial (BMT CTN 0702 /07LT). Blood cancer journal, 12(2), 27.
Raje, N. S., Anaissie, E., Kumar, S. K., Lonial, S., Martin, T., Gertz, M. A., Krishnan, A., Hari, P., Ludwig, H., O'Donnell, E., Yee, A., Kaufman, J. L., Cohen, A. D., Garderet, L., Wechalekar, A. F., Terpos, E., Khatry, N., Niesvizky, R., Yi, Q., Joshua, D. E., … Munshi, N. C. (2022). Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group. The Lancet. Haematology, 9(2), e143–e161.
Martin, T., Usmani, S. Z., Berdeja, J. G., Agha, M., Cohen, A. D., Hari, P., Avigan, D., Deol, A., Htut, M., Lesokhin, A., Munshi, N. C., O'Donnell, E., Stewart, A. K., Schecter, J. M., Goldberg, J. D., Jackson, C. C., Yeh, T. M., Banerjee, A., Allred, A., Zudaire, E., … Jagannath, S. (2023). Ciltacabtagene Autoleucel, an Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 41(6), 1265–1274.
Pan, D., Kaufman, J. L., Htut, M., Agrawal, M., Mazumder, A., Cornell, R. F., Zonder, J. A., Fay, J. W., Modiano, M. R., Moshier, E. L., Rush, S. A., Tunquist, B. J., & Chari, A. (2022). Filanesib plus bortezomib and dexamethasone in relapsed/refractory t(11;14) and 1q21 gain multiple myeloma. Cancer medicine, 11(2), 358–370.
Sanchorawala, V., Palladini, G., Minnema, M. C., Jaccard, A., Lee, H. C., Gibbs, S., Mollee, P., Venner, C., Lu, J., Schönland, S., Gatt, M., Suzuki, K., Kim, K., Cibeira, M. T., Beksac, M., Libby, E., Valent, J., Hungria, V., Wong, S. W., Rosenzweig, M., … Wechalekar, A. D. (2022). Health-related quality of life in patients with light chain amyloidosis treated with bortezomib, cyclophosphamide, and dexamethasone ± daratumumab: Results from the ANDROMEDA study. American journal of hematology, 97(6), 719–730.